Baxter announced that its Baxter BioPharma Solutions business will make Moderna‘s COVID-19 vaccine at its fill/finish sterile manufacturing facilities in Bloomington, Ind.

The plan — announced yesterday — is for Baxter to make 60–90 million doses of the Moderna vaccine in 2021.

“We have seen a remarkable demonstration of scientific and health care expertise in the effort to develop vaccines for COVID-19,” said Marie Keeley, VP of Baxter BioPharma Solutions.

Get the full story on our sister site Pharmaceutical Processing World.